Press Releases
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
Panbela Provides Business Update and Reports Q2 2024 Financial Results
Panbela to Host Q2 2024 Earnings Conference Call on 8/13/24
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial
DSMB Recommended Continuation with No Trial Modification
- DSMB Recommends Continuation without Modification for Third Time
- Safety Review Included 395 Patients
- Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
- Low Event Rate Suggests Potential for Prolonged Survival
- Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)
Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin America
Panbela Provides Business Update and Reports Q1 2024 Financial Results
Panbela Announces Issuance of New US & Canada Patent for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week (DDW)
Panbela Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial’s lower-than-expected event rate suggests improved survival outcomes
Panbela Announces Poster Presentation at American Association for Cancer Research
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
Panbela Announces Transfer to OTCQB Market
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
Panbela Announces Closing of Approximately $9.0 Million Public Offering
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer
Exceeding Anticipated Timelines with Accelerated Momentum
- Interim Data Analysis Anticipated in Mid-2024
- Expects Full Enrollment by Q1 2025
Panbela Announces Publication of Clinical Data: A New Approaches to Neuroblastoma Therapy Trial
Panbela Announces Publication of Clinical Data Titled:
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
- A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.
Panbela Announces 1-for-20 Reverse Stock Split Effective 1/18/24
Panbela Announces Exercise of Warrants, Issuance of New Warrants in Private Placement for $2M Gross Proceeds Priced At-the-Market
Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma
Panbela Announces Publication of Abstract: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
Panbela Provides Business Update and Reports Q3 2023 Financial Results
Panbela Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9M Gross Proceeds Priced At-the-Market
Panbela Announces Publication of Preclinical and Clinical Data: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D.
Panbela Announces Validation of European Patent for Claims of a Novel Process for the Production of SBP-101
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
Panbela to Host Third Quarter 2023 Earnings Conference Call on 11/9/23
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
Panbela to Present at the LD Micro Investor Conference
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Panbela Provides Business Update and Reports Q2 2023 Financial Results
Panbela to Host 2nd Quarter 2023 Earnings Conference Call on 8/10/23
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer
All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
Interim Data Analysis anticipated in Early 2024
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
Panbela Announces Issuance of New Patent in Australia
Patent is for Claims of a Novel Process for the Production of SBP-101
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
Panbela Announces Poster Presentation at the Endocrine Society Meeting
Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
Panbela Announces Closing of Approximately $8.5 Million Public Offering
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting
Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
Panbela Provides Business Update and Reports Q1 2023 Financial Results
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
Panbela Announces Poster Presentation at American Association for Cancer Research
Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
Panbela Regains Worldwide Rights to Develop and Commercialize Flynpovi™ in Patients with Familial Adenomatous Polyposis (FAP)
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd.
Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101)
Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
Panbela Announces Pricing of Approximately $15 Million Public Offering
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101)
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Announces 1-for-40 Reverse Stock Split effective 1/13/23
Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF
Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Provides Business Update and Reports Q3 2022 Financial Results
Panbela Schedules Conference Call on Nov 10, 2022 to Report 2022 Third Quarter Financial Results
November 10, 2022, 4:30 PM Eastern Time
Participant Numbers
Toll Free: 877-545-0523 / International: 973-528-0016
Participant Access Code: 598956
Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/46946
Conference Call Replay Information
Replay Number:
Toll Free: 877-481-4010 / International: 919-882-2331
Replay Passcode: 46946
Webcast Replay: https://www.webcaster4.com/Webcast/Page/2556/46946
Panbela Announces Pricing of Approximately $6 Million Public Offering
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Provides Business Update and Reports Q2 2022 Financial Results
Panbela Announces 1st Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Schedules Conference Call on 8/15/22 to Report 2022 2nd Quarter Financial Results
Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic
In vitro studies determined that SBP-101 reduced cellular viability across a broad range of cancer cell types, with an exceptionally strong reduction in ovarian adenocarcinoma viability resulting in a 42% increase in median survival in VDID8+ ovarian cancer mouse model.
Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.
Panbela Provides Business Update and Reports Q1 2022 Financial Results
Panbela to Host Virtual R&D Day
Panbela Schedules Conference Call on May 12 to Report 2022 Q1 Financial Results
Panbela Announces Poster Presentation at American Association for Cancer Research: The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer
Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results
Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28 at 12pm ET
Panbela to Participate in the 34th Annual Roth Conference
- Panbela management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT.
- The webcast will be available at: https://wsw.com/webcast/roth43/pbla/1805948
Panbela Schedules Conference Call on 3/24/22 to Report 2021 Fourth Quarter Financial Results
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.
- Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs
- Combined pipeline extends from pre-clinical to registration studies, with near-term clinical and regulatory milestones
- Acquired lead asset will begin a fully-funded registration trial anticipated to start by year-end
Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting
Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care
Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines
Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022